The earnings call highlighted significant strategic partnerships and advancements in drug development programs, notably the successful Series A financing for Neurosterix and progress in the GABAB PAM program. However, challenges remain with decreased income and cash limitations for unpartnered programs, indicating a balanced outlook.

Company Guidance -

Q2 2025

During the 2024 Full Year Financial Results Conference Call, Addex Therapeutics provided comprehensive guidance and updates on various programs and financial metrics. The company highlighted the launch of Neurosterix with a US$65 million Series A financing, alongside securing CHF5 million in cash and a 20% equity stake in Neurosterix. Addex reported making significant progress on its GABAB PAM program, with partner Indivior selecting a drug candidate for substance use disorders and initiating R&D studies. The company is eligible for up to US$330 million in milestone payments and tiered royalties. Addex also emphasized the advancement of its independent GABAB PAM program for chronic cough, aiming to start IND-enabling studies this year. Financially, the company ended 2024 with CHF3.3 million in cash, expecting it to sustain operations until mid-2026. The Neurosterix transaction was noted to have reduced cash burn and secured CHF5 million for Addex, with strategic emphasis on leveraging its 20% interest in Neurosterix for future clinical advancements.

Successful Series A Financing

In 2024, the company launched Neurosterix with a US$65 million Series A financing led by Perceptive Advisors, securing financing for the platform and pre-clinical portfolio.

Partnership with Indivior

Partner Indivior selected a compound for development in substance use disorders, with Addex eligible for up to US$330 million in milestone payments and tiered royalties.

Progress in GABAB PAM Program

Completion of the R&D phase delivered multiple drug candidates. IND-enabling studies have started for substance use disorders.

Neurosterix Spin-out

Secured CHF5 million in cash and a 20% equity interest in Neurosterix, removing financing overhang.

Development of Dipraglurant

Repositioning dipraglurant for brain injury recovery with potential for enhancing rehabilitation impact.

Addex Therapeutics (ADXN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ADXN Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Sep 01, 2025	2025 (Q2)	- / -	11.38	―	―	―
Jun 19, 2025	2025 (Q1)	- / -	-1.345	―	―
Apr 25, 2025	2024 (Q4)	- / -2.00	-1.345	-48.70% (-0.66)	―
Nov 22, 2024	2024 (Q3)	- / -	-4.115	―	―
Sep 30, 2024	2024 (Q2)	-1.42 / -2.69	-4.115	34.75% (+1.43)	―
Jun 06, 2024	2024 (Q1)	- / -	-5.367	―	―
Apr 18, 2024	2023 (Q4)	- / -1.34	-5.367	74.94% (+4.02)	―
Nov 29, 2023	2023 (Q3)	-0.66 / -4.12	11.418	-136.04% (-15.53)	―	―
Aug 10, 2023	2023 (Q2)	- / -5.49	-23.891	77.00% (+18.40)	―	―
May 11, 2023	2023 (Q1)	- / -5.37	-18.271	70.63% (+12.90)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ADXN Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Apr 25, 2025	$7.58	$8.16	+7.65%
Nov 22, 2024	$8.11	$7.53	-7.15%
Sep 30, 2024	$9.05	$9.77	+7.96%
Jun 06, 2024	$8.99	$9.20	+2.34%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Addex Therapeutics Ltd (ADR) (ADXN) report earnings?

Addex Therapeutics Ltd (ADR) (ADXN) is schdueled to report earning on Sep 01, 2025, TBA (Confirmed).

What is Addex Therapeutics Ltd (ADR) (ADXN) earnings time?

Addex Therapeutics Ltd (ADR) (ADXN) earnings time is at Sep 01, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is ADXN EPS forecast?

Currently, no data Available

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing